Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes

Diabetes Care

Volumn 23, Issue 11, 2000, Pages 1660-1665

  Horton, Edward S ^a   Clinkingbeard, Cynthia ^b   Gatlin, Marjorie ^c   Foley, James ^d   Mallows, Susan ^c   Shen, Sharon ^c  

^a JOSLIN DIABETES CENTER   (United States)

^b Idaho Endocrine Specialists   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; NATEGLINIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

EID: 0033754777     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.11.1660     Document Type: Article

References (24)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
2. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
3. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: Results from the Third National Health and Nutrition Examination Survey
4. Approaches to preventing prandial hyperglycemic excursions
5. N-acylphenylalanines and related compounds: A new class of oral hypoglycemic agents
6. N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. II. A new class of oral hypoglycemic agents
7. The metabolic advantages of a rapid onset/short acting insulin secretagogue on prandial glucose excursions
8. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
9. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
10. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
11. Efficacy of metformin in the treatment of NIDDM: Meta-analysis
12. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
13. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin: A randomized, placebo-controlled crossover study
14. Nateglinide improves prandial glucose excursions by restoring early insulin secretion in prediabetic monkeys
15. Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects
16. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus
17. Multiple sites of insulin resistance: Muscle, liver and adipose tissue
18. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial
19. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes
20. Glimepiride, a new once-daily sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
21. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
22. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
23. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry
24. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality